Summary: Researchers have identified a distinct pattern of autoantibodies in the blood that appears years before clinical symptoms of multiple sclerosis (MS) in a subset of patients. About 10% of people who later developed MS showed a unique collection of antibodies that bind both human proteins and molecular patterns found in common viruses such as Epstein-Barr virus (EBV). This discovery could enable a simple blood test for early detection and faster access to effective therapies.
The finding points to a measurable, immune-driven signature present long before MS is diagnosed, offering the potential to shift care toward earlier, more targeted intervention and improved long-term outcomes.
Key Facts:
- A consistent autoantibody signature was detected in roughly 10% of MS patients, targeting a chemical motif similar to those found in common viral pathogens.
- The study analyzed paired blood samples collected before and after diagnosis from patients in the U.S. Department of Defense Serum Repository and included 250 individuals with MS and 250 matched healthy controls.
- The identified autoantibody pattern was reproducible across independent cohorts and in the validation group it was highly predictive of later MS diagnosis, suggesting potential as a clinical biomarker.
Source: UCSF
A blood-based warning sign that precedes multiple sclerosis
Scientists at the University of California, San Francisco (UCSF) report a blood-based autoantibody signature that appears years before clinical onset in a subset of patients who go on to develop MS. In approximately one in ten cases, people produced a characteristic set of antibodies against their own proteins well before neurological symptoms emerged.
Those autoantibodies recognize structures on both human proteins and on common pathogens, which may help explain why the immune system mistakenly attacks the brain and spinal cord in MS. The study was published in Nature Medicine on April 19.
MS can cause progressive loss of motor control and other debilitating symptoms, but earlier diagnosis can allow treatment with more effective therapies that slow progression and protect function such as walking.
UCSF neurologist Michael Wilson, MD, a senior author on the paper, emphasizes that identifying patients earlier increases the chances of offering powerful treatments when they are most likely to preserve long-term quality of life.
Investigating links between infection and autoimmunity
Autoimmune disorders like MS are thought to arise, at least in part, from unusual immune responses triggered by common infections. To search for such responses, UCSF researchers adapted and improved a high-throughput technique called phage display immunoprecipitation sequencing (PhIP-Seq). PhIP-Seq displays short protein fragments on engineered viruses and screens blood samples for antibodies that bind those fragments.
The optimized PhIP-Seq platform can detect autoantibodies against more than 10,000 human proteins, making it a powerful tool for uncovering immune signatures linked to many autoimmune diseases. The team had previously used a similar approach to identify a rare cancer-related autoimmune condition.
For the current study, first co-authors Colin Zamecnik, PhD, and Gavin Sowa, MD, MS, led the laboratory work in collaboration with Mitch Wallin, MD, MPH, and others. They examined blood samples from the Department of Defense Serum Repository (DoDSR), which stores specimens collected when service members enlist. The analysis included 250 patients with MS and 250 matched healthy controls, with samples taken both after diagnosis and at least five years earlier.
This before-and-after design allowed the team to trace how autoantibody profiles evolved leading up to clinical onset. Instead of seeing a sudden rise in autoantibodies at symptom onset, they discovered a pre-existing, reproducible autoantibody cluster present years earlier in about 10% of MS cases.
A stable, virus-like autoantibody signature
The group of autoantibodies identified in these patients targeted a shared chemical motif that resembles sequences found in multiple human pathogens, including Epstein-Barr virus, which has been associated with MS in prior research. Patients with this signature also had elevated serum neurofilament light (sNfL), a marker of neuronal injury, suggesting ongoing immune-mediated damage before clinical diagnosis.
Co-author Ahmed Abdelhak, MD, found higher levels of sNfL in individuals carrying the autoantibody signature, reinforcing the idea of an immunologically active preclinical period.
As Joe DeRisi, PhD, notes, healthy individuals typically present highly individual antibody repertoires. When multiple people share the same unusual immunological signature, it signals an underlying disease process—and that is what the team observed in this MS subset.
Validation and clinical implications
To validate the discovery, researchers tested samples from the UCSF ORIGINS cohort, which includes patients with new neurological symptoms. The same autoantibody pattern was again present in roughly 10% of those later diagnosed with MS, and this pattern was highly specific to individuals who developed the disease.
Across both cohorts, the presence of this autoantibody signature reliably identified patients who would be diagnosed with MS, suggesting potential utility as a diagnostic or risk stratification tool. Wilson and colleagues hope the signature could help clinicians decide earlier whether to start disease-modifying therapy for patients with suspicious clinical or radiological findings.
Many questions remain—why this immune response develops in some patients but not others, and what drives MS in the majority who do not show this signature. Still, the study provides compelling molecular evidence of an immune-driven preclinical phase in a subset of MS patients and offers a starting point for targeted research and potential clinical testing.
“If we could diagnose MS before patients first seek care, it would change how we approach treatment,” said Stephen Hauser, MD, a senior author on the paper. Early detection improves the possibility of preventing irreversible damage and moving towards more effective long-term control of the disease.
For full details on funding, author disclosures, and the complete author list, see the published paper.
About this multiple sclerosis research news
Author: Levi Gadye
Source: UCSF
Contact: Levi Gadye – UCSF
Image: The image is credited to Neuroscience News
Original Research: Closed access. “An autoantibody signature predictive for multiple sclerosis” by Michael Wilson et al. Nature Medicine
Abstract
An autoantibody signature predictive for multiple sclerosis
Although B cells are implicated in multiple sclerosis pathophysiology, a predictive or diagnostic autoantibody has been elusive. This study used the Department of Defense Serum Repository (DoDSR) to generate whole-proteome autoantibody profiles from hundreds of individuals years before and after MS onset.
The analysis identified a distinct cluster—present in about 10% of people with MS—characterized by autoantibodies against a common motif that resembles sequences in many human pathogens. Individuals in this cluster showed antibody reactivity years before symptoms and had higher serum neurofilament light (sNfL) than other MS patients, indicating early neuronal injury. The profile persisted over time, providing molecular evidence for an immunologically active preclinical period.
Validation in an independent incident MS cohort confirmed the signature in both cerebrospinal fluid and serum and demonstrated high specificity for those later diagnosed with MS. This autoantibody signature offers a foundation for further immunological study of this MS subset and may serve as an antigen-specific biomarker to identify high-risk patients with early clinical or radiological signs of neuroinflammation.